A 12-Week, Randomized, Open-Label, Multicenter Study Exploring Low-Density Lipoprotein Cholesterol Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day Compared to10 mg/Day in Chinese Patients With Acute Coronary Syndromes
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Acute coronary syndromes
- Focus Therapeutic Use
- Acronyms ROSE
- 06 Nov 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 04 Apr 2014 New trial record